If you have room for some new portfolio additions in December, then it could be worth considering the two ASX growth shares listed below.
Hereâs what you need to know about these buy-rated shares:
Lovisa Holdings Limited (ASX: LOV)
The first ASX growth share to look at is fast-fashion jewellery retailer Lovisa. It could be a top long term option due to the popularity of its affordable offering, its focus on younger consumers, and its bold global expansion plans. In respect to the latter, the company has been expanding its footprint materially in recent years and shows no sign of stopping. In fact, it just revealed that it has added 47 net new stores so far in FY 2023, bringing its total to 676 stores across 26 countries. Management also advised that Lovisaâs first stores in Italy, Mexico, and Hungary are due to open in the coming weeks.
Macquarie currently has an outperform rating and $27.00 price target on its shares.
ResMed Inc. (ASX: RMD)
Another ASX growth share that could be in the buy zone for investors in December is ResMed. It is a medical device company with a focus on sleep treatment solutions. For many, many years, ResMed has been growing its revenue and earnings at a strong rate. This has been underpinned by the quality of its products and the growing prevalence of sleep disorders. In respect to the latter, management estimates that there are almost one billion people with sleep apnoea globally (with only ~20% diagnosed). In addition, it estimates that approximately half a billion people suffer from chronic obstructive pulmonary disease (COPD). Thanks to its leadership position in the market, this gives ResMed a long runway for growth over the 2020s and beyond.
Morgans is a fan of ResMed and currently has an add rating and $37.00 price target on its shares.
The post Analysts name 2 excellent ASX growth shares to buy in December appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now
See The 5 Stocks
*Returns as of November 1 2022
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Top brokers name 3 ASX shares to buy next week
- Iâd aim for $1 million in retirement buying just 10 ASX 200 shares
- Three comforting lessons for investors whose portfolio has been smashed versus the surprisingly good return of the ASX 200
- 4 ASX shares to buy in the sectors set to explode in 2023: expert
- ‘Dominant player’: Expert urges buying ASX shares in 2 near-monopolies
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Lovisa Holdings Ltd and ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool Australia has recommended Lovisa Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/NVksRnu